TWI790227B - 布魯頓氏酪胺酸激酶之抑制劑 - Google Patents

布魯頓氏酪胺酸激酶之抑制劑 Download PDF

Info

Publication number
TWI790227B
TWI790227B TW107112785A TW107112785A TWI790227B TW I790227 B TWI790227 B TW I790227B TW 107112785 A TW107112785 A TW 107112785A TW 107112785 A TW107112785 A TW 107112785A TW I790227 B TWI790227 B TW I790227B
Authority
TW
Taiwan
Prior art keywords
benzo
tetrahydro
amino
butyl
pyrimidin
Prior art date
Application number
TW107112785A
Other languages
English (en)
Chinese (zh)
Other versions
TW201841909A (zh
Inventor
布萊恩 T 哈柏金
馬斌
羅賓 普林斯
以撒 馬克思
喬瑟夫 P 萊多斯
鳳妹 鄭
馬修 彼得森
丹尼爾 B 佩西恩斯
Original Assignee
美商百健Ma公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ma公司 filed Critical 美商百健Ma公司
Publication of TW201841909A publication Critical patent/TW201841909A/zh
Application granted granted Critical
Publication of TWI790227B publication Critical patent/TWI790227B/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW107112785A 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑 TWI790227B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485745P 2017-04-14 2017-04-14
US62/485,745 2017-04-14

Publications (2)

Publication Number Publication Date
TW201841909A TW201841909A (zh) 2018-12-01
TWI790227B true TWI790227B (zh) 2023-01-21

Family

ID=62092333

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107112785A TWI790227B (zh) 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑
TW111149550A TWI846229B (zh) 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111149550A TWI846229B (zh) 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑

Country Status (38)

Country Link
US (5) US10227341B2 (enExample)
EP (2) EP3609886B1 (enExample)
JP (3) JP7145874B2 (enExample)
KR (3) KR102607900B1 (enExample)
CN (2) CN117567453A (enExample)
AR (2) AR111594A1 (enExample)
AU (3) AU2018253209B2 (enExample)
BR (1) BR112019021399A2 (enExample)
CA (1) CA3058774A1 (enExample)
CL (1) CL2019002900A1 (enExample)
CO (1) CO2019012571A2 (enExample)
CR (2) CR20190517A (enExample)
DK (1) DK3609886T3 (enExample)
EA (1) EA201992354A1 (enExample)
ES (1) ES2975769T3 (enExample)
FI (1) FI3609886T3 (enExample)
HR (1) HRP20240361T1 (enExample)
HU (1) HUE066253T2 (enExample)
IL (3) IL316713A (enExample)
JO (1) JOP20190233A1 (enExample)
LT (1) LT3609886T (enExample)
MA (1) MA50013B1 (enExample)
MD (1) MD3609886T2 (enExample)
MX (1) MX2023000812A (enExample)
NZ (1) NZ757929A (enExample)
PE (2) PE20200740A1 (enExample)
PH (1) PH12019502334A1 (enExample)
PL (1) PL3609886T3 (enExample)
PT (1) PT3609886T (enExample)
RS (1) RS65386B1 (enExample)
SA (1) SA519410292B1 (enExample)
SG (1) SG11201909224QA (enExample)
SI (1) SI3609886T1 (enExample)
SM (1) SMT202400166T1 (enExample)
TW (2) TWI790227B (enExample)
UA (1) UA127347C2 (enExample)
WO (1) WO2018191577A1 (enExample)
ZA (1) ZA202306172B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2678021T3 (es) 2013-12-11 2018-08-08 Biogen Ma Inc. Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
EP3866926A1 (en) 2018-10-15 2021-08-25 Biogen MA Inc. Crystalline polymorphs of bruton's tyrosine kinase inhibitors
US12240838B2 (en) 2019-05-15 2025-03-04 Biogen Ma Inc. Inhibiting agents for Bruton's tyrosine kinase
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
CN118804915A (zh) 2021-11-10 2024-10-18 渤健马萨诸塞州股份有限公司 Btk抑制剂
JP2023140319A (ja) 2022-03-22 2023-10-04 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
WO2014125444A1 (en) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2015089337A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2010522241A (ja) 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
CA2701581C (en) 2007-10-05 2016-12-20 S*Bio Pte Ltd Pyrimidine substituted purine derivatives
CA2716898A1 (en) 2008-02-27 2009-09-03 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
SI2734522T1 (sl) 2011-07-19 2019-03-29 Merck Sharp & Dohme B.V. 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDI IN 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI kot BTK-INHIBITORJI
WO2014130856A2 (en) 2013-02-21 2014-08-28 Wayne Rothbaum Treatment of skeletal-related disorders
SG10201901902WA (en) 2013-10-21 2019-04-29 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
KR102523111B1 (ko) * 2014-10-06 2023-04-18 메르크 파텐트 게엠베하 Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
WO2014125444A1 (en) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2015089337A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Also Published As

Publication number Publication date
TWI846229B (zh) 2024-06-21
EP3609886A1 (en) 2020-02-19
US20210340135A1 (en) 2021-11-04
JP2022180498A (ja) 2022-12-06
MA50013B1 (fr) 2024-05-31
CA3058774A1 (en) 2018-10-18
SI3609886T1 (sl) 2024-05-31
US11427577B2 (en) 2022-08-30
SA519410292B1 (ar) 2023-03-12
MX2023000812A (es) 2023-02-27
IL269933A (enExample) 2019-11-28
EP4249071A3 (en) 2024-01-24
JP2020516659A (ja) 2020-06-11
AU2018253209B2 (en) 2022-06-02
JP7581294B2 (ja) 2024-11-12
KR102607900B1 (ko) 2023-11-29
US11858926B2 (en) 2024-01-02
US10961237B2 (en) 2021-03-30
CN110621670B (zh) 2023-09-15
TW202315870A (zh) 2023-04-16
AU2018253209A1 (en) 2019-10-31
PL3609886T3 (pl) 2024-05-13
WO2018191577A1 (en) 2018-10-18
JP7778206B2 (ja) 2025-12-01
MD3609886T2 (ro) 2024-07-31
AU2022218560B2 (en) 2024-04-04
PE20240930A1 (es) 2024-04-30
PH12019502334A1 (en) 2020-09-21
SMT202400166T1 (it) 2024-07-09
EP3609886B1 (en) 2024-02-07
IL294175B2 (en) 2025-04-01
ES2975769T3 (es) 2024-07-15
KR20190139926A (ko) 2019-12-18
CO2019012571A2 (es) 2020-01-17
DK3609886T3 (da) 2024-03-18
FI3609886T3 (fi) 2024-03-26
CL2019002900A1 (es) 2020-01-24
RS65386B1 (sr) 2024-04-30
CN110621670A (zh) 2019-12-27
HRP20240361T1 (hr) 2024-06-07
AR129632A2 (es) 2024-09-11
US20230147490A1 (en) 2023-05-11
US20180297992A1 (en) 2018-10-18
IL269933B (en) 2022-07-01
EA201992354A1 (ru) 2020-03-10
ZA202306172B (en) 2024-11-27
KR102862996B1 (ko) 2025-09-22
LT3609886T (lt) 2024-04-10
AU2024204241A1 (en) 2024-07-11
NZ757929A (en) 2025-10-31
SG11201909224QA (en) 2019-11-28
AU2022218560A1 (en) 2022-09-15
PT3609886T (pt) 2024-04-11
AR111594A1 (es) 2019-07-31
CR20230539A (es) 2024-04-08
CR20190517A (es) 2020-02-13
PE20200740A1 (es) 2020-07-24
IL294175B1 (en) 2024-12-01
HUE066253T2 (hu) 2024-07-28
CN117567453A (zh) 2024-02-20
IL316713A (en) 2024-12-01
US10227341B2 (en) 2019-03-12
JP7145874B2 (ja) 2022-10-03
EP4249071A2 (en) 2023-09-27
IL294175A (en) 2022-08-01
US10189829B2 (en) 2019-01-29
TW201841909A (zh) 2018-12-01
KR20230164247A (ko) 2023-12-01
US20180362522A1 (en) 2018-12-20
BR112019021399A2 (pt) 2020-04-28
US20200239459A1 (en) 2020-07-30
KR20250140646A (ko) 2025-09-25
UA127347C2 (uk) 2023-07-26
MA50013A (fr) 2020-07-08
JOP20190233A1 (ar) 2019-10-02
JP2025020247A (ja) 2025-02-12

Similar Documents

Publication Publication Date Title
TWI790227B (zh) 布魯頓氏酪胺酸激酶之抑制劑
HK40100583A (en) Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase
EA040817B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона
HK40022870A (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
HK40022870B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
EA047837B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона